AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and six months ended 30 September 2022

'Rs in lakhs except for earnings per share data

Sl No.	Particulars	3 months ended 30/09/2022	Previous 3 months ended 30/06/2022	Corresponding 3 months ended in the previous year 30/09/2021	6 months ended 30/09/2022	6 months ended 30/09/2021	Year ended 31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	a) Revenue from operations	23,612.68	23,233.20	19,770.76	46,845.88	37,310.96	80,560.01
	b) Other income	679.43	411.42	284.33	1,090.85	574.31	1,475.76
	Total income	**24,292.11**	**23,644.62**	**20,055.09**	**47,936.73**	**37,885.27**	**82,035.77**
2	**Expenses**						
	(a) Cost of materials consumed	1,976.26	1,589.15	2,263.38	3,565.41	4,031.33	8,961.06
	(b) Purchase of stock-in-trade	7,118.49	7,531.44	7,441.66	14,649.93	10,747.54	20,788.07
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(444.97)	(782.60)	(1,679.27)	(1,227.57)	(106.29)	1,447.01
	(d) Employee benefit expense	6,118.74	6,837.12	5,788.69	12,955.86	11,268.03	23,020.62
	(e) Depreciation expense	328.70	459.18	427.57	787.88	903.65	1,694.89
	(f) Allowance for expected credit loss (net)	(19.26)	99.00	80.26	79.74	209.51	399.93
	(g) Selling, marketing and distribution expense	1,443.24	1,073.50	983.80	2,516.74	2,012.25	5,071.91
	(h) Other expenses	3,347.72	4,089.31	3,100.60	7,437.03	5,793.86	12,253.94
	(i) Finance costs	16.25	18.62	24.69	34.87	51.28	94.72
	Total expenses	**19,885.17**	**20,914.72**	**18,431.38**	**40,799.89**	**34,911.16**	**73,732.15**
3	**Profit before tax (1-2)**	**4,406.94**	**2,729.90**	**1,623.71**	**7,136.84**	**2,974.11**	**8,303.62**
4	**Tax expense**						
	- Current tax	1,239.99	767.51	477.22	2,007.50	893.87	2,262.94
	- Deferred tax credit	(89.48)	(52.87)	(48.21)	(142.35)	(138.79)	(118.60)
	Total tax expense	**1,150.51**	**714.64**	**429.01**	**1,865.15**	**755.08**	**2,144.34**
5	**Profit after tax (3-4)**	**3,256.43**	**2,015.26**	**1,194.70**	**5,271.69**	**2,219.03**	**6,159.28**
6	**Other comprehensive income/(loss)**						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	(24.85)	(9.45)	(46.30)	(34.30)	(58.62)	(231.59)
	Income tax effect on above	6.25	2.38	11.65	8.63	14.75	58.29
	Total other comprehensive income/ (loss), net of income tax	**(18.60)**	**(7.07)**	**(34.65)**	**(25.67)**	**(43.87)**	**(173.30)**
	Total comprehensive income for the period (5+6)	**3,237.83**	**2,008.19**	**1,160.05**	**5,246.02**	**2,175.16**	**5,985.98**
7	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**
8	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	-	-	50,639.29
9	**Earnings per equity share of Rs 2/- each (basic and diluted)**	**13.03**	**8.06**	**4.78**	**21.09**	**8.88**	**24.64**

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

11/11/22

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and six months ended 30 September 2022

Notes:

1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.

3 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.

4 This statement of financial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 11 November 2022. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 September 2022.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Gagandeep Singh Bedi
Managing Director

Place: Bengaluru
Date: 11 November, 2022

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited
Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of assets and liabilities

(Rs in lakhs)

Sl.No.	Balance Sheet	As at 30 September 2022 Unaudited	As at 31 March 2022 Audited
	ASSETS		
1	**Non-current assets**		
	(a) Property, plant and equipment	6,304.87	6,708.42
	(b) Right-of-use assets	560.77	741.35
	(c) Capital work-in-progress	295.54	220.39
	(d) Financial Assets		
	(i) Loans	69.95	40.94
	(ii) Other financial assets	326.60	293.02
	(e) Non-current tax assets (net)	5,156.85	5,156.85
	(f) Deferred tax assets (net)	1,780.81	1,628.83
	(g) Other non-current assets	311.32	299.03
	Sub-total - Non-current assets	**14,806.71**	**15,088.83**
2	**Current assets**		
	(a) Inventories	16,101.45	14,021.93
	(b) Financial Assets		
	(i) Trade receivables	8,866.06	8,588.66
	(ii) Cash and cash equivalents	46,967.72	44,841.69
	(iii) Bank balances other than cash and cash equivalents	6.33	4.11
	(iv) Loans	13.58	8.81
	(v) Other financial assets	1,513.19	1,226.91
	(c) Other current assets	1,360.08	1,874.49
	Sub-total - Current assets	**74,828.41**	**70,566.60**
	TOTAL - ASSETS	**89,635.12**	**85,655.43**
1	**EQUITY AND LIABILITIES**		
	Equity		
	(a) Equity Share capital	500.00	500.00
	(b) Other Equity	53,868.26	50,639.29
	Sub-total - Shareholders' funds	54,368.26	51,139.29
	LIABILITIES		
	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Lease liabilities	338.84	501.64
	(b) Provisions	749.93	749.93
	Sub-total - Non-current liabilities	1,088.77	1,251.57
2	**Current liabilities**		
	(a) Financial Liabilities		
	(i) Lease liabilities	327.98	360.82
	(ii) Trade payables		
	Total outstanding dues of micro and small enterprises	223.23	78.69
	Total outstanding dues of creditors other than micro and small enterprises	19,050.14	18,726.84
	(iii) Other financial liabilities	4,166.46	4,972.16
	(b) Provisions	4,205.83	4,016.99
	(c) Current tax liabilities (net)	930.32	493.83
	(d) Other current liabilities	5,274.13	4,615.24
	Sub-total - Current liabilities	34,178.09	33,264.57
	TOTAL - EQUITY AND LIABILITIES	**89,635.12**	**85,655.43**

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited

Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of cash flows

(Rs in lakhs)

Particulars	Six months ended 30 September 2022 Unaudited	Six months ended 30 September 2021 Unaudited
A) Cash flow from operating activities		
Profit before tax	**7,136.84**	**2,974.11**
Non-cash adjustments for :		
Depreciation and impairment expense	787.88	903.65
(Profit) on sale of property, plant and equipment (net)	(165.49)	(31.33)
Interest income on deposits carried at amortised cost	(866.16)	(541.77)
Employee stock compensation expense	58.99	92.20
Unrealised foreign exchange gain (net)	(2.06)	10.88
Allowance for expected credit loss (net)	79.74	209.51
Finance costs	34.87	51.28
Operating profit before working capital changes	**7,064.61**	**3,668.53**
Changes in working capital:		
(Increase) / Decrease in trade receivables	(357.13)	84.80
(Increase) / Decrease in inventories	(2,079.53)	111.43
(Increase) / Decrease in loans	(33.78)	6.28
(Increase) / Decrease in other financial assets	(311.16)	67.49
(Increase) / Decrease in other assets	514.18	301.31
Increase / (Decrease) in trade payables	469.92	1,987.62
Increase / (Decrease) in provisions	163.17	145.28
Increase / (Decrease) in other financial liabilities	(873.40)	(411.38)
Increase / (Decrease) in other liabilities	658.89	859.03
Cash generated from operations	**5,215.77**	**6,820.39**
Income taxes paid (net of refund)	(1,579.64)	(1,668.90)
Net cash generated from operating activities (A)	**3,636.13**	**5,151.49**
B) Cash flows from investing activities		
Interest income on bank deposits	855.24	528.87
Purchase of property, plant and equipment, including capital work-in-progress	(397.61)	(552.82)
Proceeds from sale of property, plant and equipment	262.79	42.45
Net cash generated from / (used in) investing activities (B)	**720.42**	**18.50**
C) Cash flows from financing activities		
Principal payment of lease liabilities	(195.65)	(169.84)
Interest cost on lease liabilities	(34.87)	(51.28)
Dividend paid	(2,000.00)	(500.00)
Net cash generated from/ (used in) financing activities (C)	**(2,230.52)**	**(721.12)**
D) Net increase/ (decrease) in cash and cash equivalents (A+B+C)	**2,126.03**	**4,448.87**
E) Cash and cash equivalents at the beginning of the period	**44,841.69**	**35,233.81**
F) Cash and cash equivalents at the end of the period (D+E)	**46,967.72**	**39,682.68**

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter and six months ended 30 September 2022

				Rs in lakhs except for earnings per share data
Sl No.	Particulars	3 months ended 30/09/2022	Year to date figure for current period ended 30/09/2022	Corresponding 3 months ended in the previous year 30/09/2021
		Unaudited	Unaudited	Unaudited
1	Total income from operations	24,292.11	47,936.73	20,055.09
2	Net profit/(loss) for the period from ordinary activities before tax	4,406.94	7,136.84	1,623.71
3	Net profit/(loss) for the period from ordinary activities after tax	3,256.43	5,271.69	1,194.70
4	Total comprehensive income for the period after tax	3,237.83	5,246.02	1,160.05
5	Equity Share Capital	500.00	500.00	500.00
6	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-
7	Basic and diluted earnings per share (of Rs 2 each)	13.03	21.09	4.78

Note:

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites.(www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).

2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Gagandeep Singh Bedi
Managing Director

Place: Bengaluru
Date: 11 November, 2022